Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Khalil

Showing results (201-210 of 450) with videos related to

Pageof 45
Sort By:
Ecotoxicology and Environmental Safety|June 29, 2023
Nephroprotective effects of Acacia senegal against aflatoxicosis via targeting inflammatory and apoptotic signaling pathwaysObeid Shanab, Samir M El-Rayes, Waleed F Khalil, et al.
Future Oncology (London, England)|September 17, 2020
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancerRobert A Huddart, Arlene O Siefker-Radtke, Arjun V Balar, et al.
American Journal of Human Genetics|January 9, 2008
Independent introduction of two lactase-persistence alleles into human populations reflects different history of adaptation to milk cultureNabil Sabri Enattah, Tine G K Jensen, Mette Nielsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2021
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyAjjai S Alva, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
European Journal of Cancer (Oxford, England : 1990)|May 2, 2021
Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance])Harry H Yoon, Fang-Shu Ou, Gamini S Soori, et al.
The New England Journal of Medicine|March 25, 2026
Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon CancerFrank A Sinicrope, Fang-Shu Ou, Dirk Arnold, et al.
JACC. Cardiovascular Interventions|June 30, 2025
30-Day and 1-Year Outcomes From the Optimize PRO TAVR Evolut FX Addendum StudyHemal Gada, Ramzi F Khalil, Stanley J Chetcuti, et al.
JAMA Cardiology|October 9, 2024
Transcatheter Aortic Valve Implantation by Valve Type in Women With Small Annuli: Results From the SMART Randomized Clinical TrialDidier Tchétché, Roxana Mehran, Daniel J Blackman, et al.
JCO Precision Oncology|October 16, 2024
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyFrancis P Worden, Evan Pisick, Michael Rothe, et al.
JACC. Cardiovascular Interventions|June 1, 2026
First Large Comprehensive Core-Laboratory Evaluation of Implantation Depth and Clinical Outcomes in TAVR: Final Global Results from the Optimize PRO Prospective StudyDanny Dvir, Hasan A Jilaihawi, Douglas Fraser, et al.
Pageof 45

Showing results (201-210 of 450) with videos related to

Sort By:
Pageof 45
Ecotoxicology and Environmental Safety|June 29, 2023
Nephroprotective effects of Acacia senegal against aflatoxicosis via targeting inflammatory and apoptotic signaling pathwaysObeid Shanab, Samir M El-Rayes, Waleed F Khalil, et al.
Future Oncology (London, England)|September 17, 2020
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancerRobert A Huddart, Arlene O Siefker-Radtke, Arjun V Balar, et al.
American Journal of Human Genetics|January 9, 2008
Independent introduction of two lactase-persistence alleles into human populations reflects different history of adaptation to milk cultureNabil Sabri Enattah, Tine G K Jensen, Mette Nielsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2021
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyAjjai S Alva, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
European Journal of Cancer (Oxford, England : 1990)|May 2, 2021
Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance])Harry H Yoon, Fang-Shu Ou, Gamini S Soori, et al.
The New England Journal of Medicine|March 25, 2026
Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon CancerFrank A Sinicrope, Fang-Shu Ou, Dirk Arnold, et al.
JACC. Cardiovascular Interventions|June 30, 2025
30-Day and 1-Year Outcomes From the Optimize PRO TAVR Evolut FX Addendum StudyHemal Gada, Ramzi F Khalil, Stanley J Chetcuti, et al.
JAMA Cardiology|October 9, 2024
Transcatheter Aortic Valve Implantation by Valve Type in Women With Small Annuli: Results From the SMART Randomized Clinical TrialDidier Tchétché, Roxana Mehran, Daniel J Blackman, et al.
JCO Precision Oncology|October 16, 2024
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyFrancis P Worden, Evan Pisick, Michael Rothe, et al.
JACC. Cardiovascular Interventions|June 1, 2026
First Large Comprehensive Core-Laboratory Evaluation of Implantation Depth and Clinical Outcomes in TAVR: Final Global Results from the Optimize PRO Prospective StudyDanny Dvir, Hasan A Jilaihawi, Douglas Fraser, et al.
Pageof 45